CTTI is pleased to announce the addition of two experienced patient advocates to its Executive Committee:
Donna Cryer is the CEO of the Global Liver Institute, which promotes innovation and fosters collaboration to improve the health of patients with liver disease.
Pat Furlong is the founder and CEO of Parent Project Muscular Dystrophy, which works to end Duchenne muscular dystrophy by accelerating research and advocating for optimal patient care.
“CTTI recognizes the importance of meaningful patient engagement in both our organizational structure and project work, and in the broader clinical trials enterprise,” said CTTI Executive Director Pamela Tenaerts. “We are excited for Donna and Pat to serve on our Executive Committee and ensure that the patient voice is represented in decisions regarding CTTI’s direction and strategy.”
As members of the Executive Committee, Cryer and Furlong will offer valuable perspectives in driving toward CTTI’s vision of a high-quality clinical trials system that is patient-centered and efficient. They bring decades of experience in patient and caregiver advocacy in the nonprofit sector. Both have served as advisers and consultants to government agencies, professional societies, and advocacy organizations.
“CTTI’s mission to increase the quality and efficiency of clinical trials is achievable when we have the broadest range of stakeholders at the table,” said CTTI Executive Committee Chair Mark McClellan. “Donna and Pat will strengthen our ability to promote patient and caregiver engagement across the clinical trials enterprise.”
The two new CTTI Executive Committee members join a distinguished group of thought leaders with the knowledge and experience to make meaningful improvements in clinical research.
Donna Cryer Pat Furlong